DaVita Beheer

Beheer criteriumcontroles 2/4

De CEO DaVita is Javier Rodriguez, benoemd in Jun2019, heeft een ambtstermijn van 5.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.71M, bestaande uit 21% salaris en 79% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.02% van de aandelen van het bedrijf, ter waarde € 132.36M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 4.3 jaar.

Belangrijke informatie

Javier Rodriguez

Algemeen directeur

US$6.7m

Totale compensatie

Percentage CEO-salaris	21.0%
Dienstverband CEO	5.4yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Javier Rodriguez's beloning veranderd ten opzichte van DaVita's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$828m
Jun 30 2024	n/a	n/a	US$860m
Mar 31 2024	n/a	n/a	US$816m
Dec 31 2023	US$7m	US$1m	US$692m
Sep 30 2023	n/a	n/a	US$596m
Jun 30 2023	n/a	n/a	US$454m
Mar 31 2023	n/a	n/a	US$500m
Dec 31 2022	US$3m	US$1m	US$547m
Sep 30 2022	n/a	n/a	US$680m
Jun 30 2022	n/a	n/a	US$834m
Mar 31 2022	n/a	n/a	US$903m
Dec 31 2021	US$3m	US$1m	US$978m
Sep 30 2021	n/a	n/a	US$984m
Jun 30 2021	n/a	n/a	US$883m
Mar 31 2021	n/a	n/a	US$791m
Dec 31 2020	US$73m	US$1m	US$783m
Sep 30 2020	n/a	n/a	US$832m
Jun 30 2020	n/a	n/a	US$824m
Mar 31 2020	n/a	n/a	US$816m
Dec 31 2019	US$17m	US$1m	US$705m
Sep 30 2019	n/a	n/a	US$623m
Jun 30 2019	n/a	n/a	US$548m
Mar 31 2019	n/a	n/a	US$551m
Dec 31 2018	US$8m	US$900k	US$616m
Sep 30 2018	n/a	n/a	US$617m
Jun 30 2018	n/a	n/a	US$698m
Mar 31 2018	n/a	n/a	US$652m
Dec 31 2017	US$8m	US$900k	US$909m

Compensatie versus markt: De totale vergoeding ($USD 6.71M ) Javier } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.74M ).

Compensatie versus inkomsten: De vergoeding van Javier is het afgelopen jaar met meer dan 20% gestegen.

CEO

Javier Rodriguez (53 yo)

5.4yrs

Tenure

US$6,712,328

Compensatie

Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Javier Rodriguez	CEO & Executive Director	5.4yrs	US$6.71m	1.02% € 132.4m
Joel Ackerman	CFO & Treasurer	7.8yrs	US$6.87m	0.11% € 14.7m
Kathleen Waters	Chief Legal & Public Affairs Officer	8.5yrs	US$5.61m	0.071% € 9.2m
James Hearty	Chief Compliance Officer	6.7yrs	US$2.73m	0.015% € 1.9m
David Maughan	Chief Operating Officer	less than a year	geen gegevens	0.0073% € 950.8k
Christopher Berry	Group VP & Chief Accounting Officer	1.3yrs	geen gegevens	geen gegevens
Madhu Narasimhan	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Nic Eliason	Group Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Jessica Hergenreter	Chief People Officer	less than a year	geen gegevens	geen gegevens
Misha Palecek	Chief Transformation Officer of U.S. Kidney Care Business	no data	geen gegevens	geen gegevens
Jeffrey Giullian	Chief Medical Officer of Kidney Care	4.8yrs	geen gegevens	geen gegevens
Partha Das	Chief Medical Officer of DaVita International	6.3yrs	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TRL is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Javier Rodriguez	CEO & Executive Director	5.4yrs	US$6.71m	1.02% € 132.4m
Charles Berg	Director	17.7yrs	US$322.46k	0.032% € 4.2m
Barbara Desoer	Independent Director	9.1yrs	US$384.96k	0.015% € 1.9m
Phyllis Yale	Independent Director	8.3yrs	US$374.96k	0.020% € 2.5m
Wendy Schoppert	Independent Director	1.3yrs	US$106.86k	0.0022% € 288.9k
Pamela Arway	Independent Chair	15.5yrs	US$497.46k	0.030% € 3.9m
Dennis Pullin	Independent Director	less than a year	geen gegevens	0.00075% € 97.2k
Adam Schechter	Independent Director	2.2yrs	US$334.96k	0.0044% € 573.9k
Jason Hollar	Independent Director	2.5yrs	US$364.96k	0.0055% € 717.7k
Gregory Moore	Independent Director	3.2yrs	US$355.89k	0.0070% € 909.4k

4.3yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TRL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

DaVita Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

DaVita Appoints Jessica Hergenreter as Chief People Officer

CEO & Executive Director recently sold €8.9m worth of stock

DaVita Announces Executive Appointments, Effective September 15, 2024

CEO & Executive Director recently sold €5.6m worth of stock

Chief Legal & Public Affairs Officer recently sold €1.0m worth of stock

Independent Director recently sold €648k worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: US$2.56 (vs US$2.70 in 3Q 2023)

DaVita Appoints Jessica Hergenreter as Chief People Officer

DaVita Inc. to Report Q3, 2024 Results on Oct 29, 2024

CEO & Executive Director recently sold €8.9m worth of stock

DaVita Announces Executive Appointments, Effective September 15, 2024

CEO & Executive Director recently sold €5.6m worth of stock

New major risk - Revenue and earnings growth

Chief Legal & Public Affairs Officer recently sold €1.0m worth of stock

Second quarter 2024 earnings released: EPS: US$2.56 (vs US$1.96 in 2Q 2023)

DaVita Inc. to Report Q2, 2024 Results on Aug 06, 2024

Now 20% overvalued after recent price rise

Now 18% overvalued after recent price rise

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Independent Director recently sold €648k worth of stock

DaVita Appoints Madhu Narasimhan as Chief Information Officer, Effective June 3, 2024

First quarter 2024 earnings released: EPS: US$2.73 (vs US$1.28 in 1Q 2023)

DaVita Inc., Annual General Meeting, Jun 06, 2024

High number of new directors

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

Chief Compliance Officer recently sold €2.8m worth of stock

Full year 2023 earnings released: EPS: US$7.62 (vs US$5.88 in FY 2022)

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

Investor sentiment improves as stock rises 16%

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$2.70 (vs US$1.16 in 3Q 2022)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 20%

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$1.96 (vs US$2.38 in 2Q 2022)

DaVita Inc. Announces Management Changes

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chief Legal & Public Affairs Officer recently sold €916k worth of stock

First quarter 2023 earnings released: EPS: US$1.28 (vs US$1.68 in 1Q 2022)

Director recently sold €102k worth of stock

Full year 2022 earnings released: EPS: US$5.88 (vs US$9.30 in FY 2021)

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Independent Director recently bought €360k worth of stock

Third quarter 2022 earnings released: EPS: US$1.16 (vs US$2.48 in 3Q 2021)

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita Inc. Appoints Adam H. Schechter to Board of Directors

Second quarter 2022 earnings released: EPS: US$2.38 (vs US$2.76 in 2Q 2021)

DaVita Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Operating Officer of Kidney Care recently bought €1.5m worth of stock

Investor sentiment deteriorated over the past week

Independent Director recently sold €211k worth of stock

DaVita Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings released: EPS: US$1.68 (vs US$2.18 in 1Q 2021)

DaVita Inc. to Report Q1, 2022 Results on May 05, 2022

DaVita Inc. Appoints Jason M. Hollar as Independent Director

Independent Director recently sold €70k worth of stock

DaVita Inc. (NYSE:DVA) acquired 17 Dialysis Centers in United States.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

DaVita Inc. to Report Q4, 2021 Results on Feb 10, 2022

DaVita Inc. (NYSE:DVA) acquired MedSleuth, Inc.

Third quarter 2021 earnings released: EPS US$2.48 (vs US$1.31 in 3Q 2020)

Independent Director recently sold €89k worth of stock

Second quarter 2021 earnings released: EPS US$2.76 (vs US$1.65 in 2Q 2020)

DaVita Inc. (NYSE:DVA) acquired a Dialysis Center in US.

Davita's China Affiliate to Invest in Hunan Fangsheng Pharma's Unit for 31.7% Stake

First quarter 2021 earnings released: EPS US$2.18 (vs US$1.84 in 1Q 2020)

New 90-day low: €86.00

Full year 2020 earnings released: EPS US$6.54 (vs US$4.61 in FY 2019)

Revenue misses expectations

Kyros Law Files Legal Claims on Behalf of Davita Inc Investors

DaVita Inc. to Report Q4, 2020 Results on Feb 11, 2021

Renalytix AI plc and DaVita Announce Partnership

New 90-day high: €94.83